Covered recipient · General Payments record
ABIGAIL ADAMS ECKARD
Physician Assistants & Advanced Practice Nursing Providers Physician Assistant Medical
General Payments · PY2023–2024
$445.20
- Reported across 24 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $283.77 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $92.27 | 6 |
| Lilly USA, LLC | $74.60 | 4 |
| Organon LLC | $26.59 | 1 |
| GlaxoSmithKline, LLC. | $23.74 | 1 |
| Acerta Pharma LLC | $17.73 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $16.36 | 1 |
| Exact Sciences Corporation | $16.27 | 1 |
| Astellas Pharma US Inc | $16.21 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Astellas Pharma US Inc | $16.21 | 06/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139516261 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.73 | 08/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105563068 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $16.36 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118037490 | CMS |
| Exact Sciences Corporation | $16.27 | 10/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114420417 | CMS |
| GlaxoSmithKline, LLC. | $23.74 | 11/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116207234 | CMS |
| Lilly USA, LLC | $17.87 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135522299 | CMS |
| Lilly USA, LLC | $13.44 | 04/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135509060 | CMS |
| Lilly USA, LLC | $20.25 | 07/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135522301 | CMS |
| Lilly USA, LLC | $23.04 | 09/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135480385 | CMS |
| Novo Nordisk Inc | $17.52 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100382323 | CMS |
| Novo Nordisk Inc | $15.71 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100627234 | CMS |
| Novo Nordisk Inc | $13.20 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100455734 | CMS |
| Novo Nordisk Inc | $15.99 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100426170 | CMS |
| Novo Nordisk Inc | $16.54 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100508283 | CMS |
| Novo Nordisk Inc | $13.31 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100492887 | CMS |
| Organon Llc | $26.59 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136217959 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2023, 2024
- Source files
- Dataset page · Bulk file · PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.